Does highly active antiretroviral therapy improve neurocognitive function? A systematic review

Journal of NeuroVirology

Volumn 16, Issue 2, 2010, Pages 101-114

  Joska, John A ^a   Gouse, Hetta ^a   Paul, Robert H ^b   Stein, Dan J ^a   Flisher, Alan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF MISSOURI ST LOUIS   (United States)

Author keywords

HIV dementia; HIV AIDS; Neuropsychology

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIOMMUNE; UNCLASSIFIED DRUG; ZIDOVUDINE;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE CLASSIFICATION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFORMATION RETRIEVAL; LONG TERM CARE; MEDLINE; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PSYCINFO; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; HUMANS; INCIDENCE; NEUROPSYCHOLOGICAL TESTS; PREVALENCE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77952149363     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550281003682513     Document Type: Review

References (53)

1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson K.R, Sacktor N, Valcour V,Wojna VE (2007a).Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789-1799.
2. Brew BJ (2004). Evidence for a change in AIDS dementia complex in the era of highly active anti-retroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 18(Suppl 1): S75-S78.
3. Carvalhal AS, Rourke SB, Belmonte-Abreu P, Correa J, Goldani LZ (2006). Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active anti-retroviral therapy. Infection 34: 357-360.
4. Chang L (1999). Highly active anti-retroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 53: 782-789.
5. Cherner M, Cysique L, Heaton RK, Marcotte TD, Ellis RJ, Masliah E, Grant I (2007). Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J NeuroVirol 13: 23-28.
6. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, Heaton RK (2002). Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59: 1563-1567.
7. Cherner M, Suarez P, Posada C, Fortuny LA, Marcotte T, Grant I, Heaton R (2008). Equivalency of Spanish language versions of the trail making test part B including or excluding "CH". Clin Neuropsychol 22: 662-665.
8. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B (2000). Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 14: 1949-1954.
9. Cysique LA, Brew BJ (2009). Neuropsychological functioning and anti-retroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 19: 169-185.
10. Cysique LA, Jin H, Franklin DR Jr, Morgan EE, Shi C, Yu X, Wu Z, Taylor MJ, Marcotte TD, Letendre S, Ake C, Grant I, Heaton RK (2007). Neurobehavioral effects of HIV-1 infection in China and the United States: a pilot study. J Int Neuropsychol Soc 13: 781-790.
11. Cysique LA, Maruff P, Brew BJ (2004). Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active anti-retroviral therapy eras: a combined study of two cohorts. J NeuroVirol 10: 350-357.
12. Cysique LA, Maruff P, Brew BJ (2006). The neuropsycho-logical profile of symptomatic AIDS and ADC patients in the pre-HAART era: a meta-analysis. J Int Neuropsy-chol Soc 12: 368-382.
13. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ (2009). Dynamics of cognitive change in impaired HIV-positive patients initiating anti-retroviral therapy. Neurology 73: 342-348.
14. Ferrando S, Van GW, McElhiney M, Goggin K, Sewell M, Rabkin J (1998). Highly active anti-retroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 12: F65-F70.
15. Ferrando SJ, Rabkin JG, Van GW, Lin SH, McElhiney M (2003). Longitudinal improvement in psychomotor processing speed is associated with potent combination anti-retroviral therapy in HIV-1 infection. J Neuropsy-chiatry Clin Neurosci 15: 208-214.
16. Grant I (2008). Neurocognitive disturbances in HIV. Int Rev Psychiatry 20: 33-47.
17. Grant I, Sacktor N, McArthur JC (2005). HIV and neuro-cognitive disorders. In: The neurology of AIDS. Gendelman H, Grant I, Everall I, Lipton S, Swindells S (eds.). Oxford, UK: Oxford University Press, pp 359-374.
18. Gupta JD, Satishchandra P, Gopukumar K, Wilkie F, Waldrop-Valverde D, Ellis R, Ownby R, Subbakrishna DK, Desai A, Kamat A, Ravi V, Rao BS, Satish KS, Kumar M (2007). Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J NeuroVirol 13: 195-202.
19. Hightower GK, Letendre SL, Cherner M, Gibson SA, Ellis RJ, Wolfson TJ, Gamst AC, Ignacio CC, Heaton RK, Grant I, Richman DD, Smith DM (2009). Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance. Virology 394: 243-248.
20. Janssen RS, Cornblath DR, Epstein LG, McArthur J, Price RW (1991). Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 41: 778-785.
21. Joska JA, Thomas KG, Stein DJ, Seedat S, Carey PD, Laidlaw D, Paul RH (2009). Neuropsychological profile of patients commencing HAART in Cape Town South Africa\preliminary findings [unpublished work].
22. Kanki P, Hamel D, Sankale J, Hsieh C, Thior I, Barin F, Woodcock S, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, Ndoye I, Essex M, Mboup S (1999). Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 179: 68-73.
23. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, Eller M, Makumbi F, Wabire-Mangen F, Serwadda D, Sewankambo N, Quinn T, Wawer M, Gray R (2008). Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 197: 707-713.
24. Lawton MP, Brody EM (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179-186.
25. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ (2008). Validation of the CNS penetration-effectiveness rank for quantifying anti-retroviral penetration into the central nervous system. Arch Neurol 65: 65-70.
26. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ (2004). Enhancing anti-retroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 56: 416-423.
27. Manly JJ (2005). Advantages and disadvantages of separate norms for African Americans. Clin Neuropsychol 19: 270-275.
28. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K (2009). Impact of combination anti-retroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23: 1359-1366.
29. McArthur JC (2004). HIV dementia: an evolving disease. J Neuroimmunol 157: 3-10.
30. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NM, McArthur JH, Selnes OA, Jacobson LP (1993). Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43: 2245-2252.
31. McCutchan JA, Wu JW, Robertson K, Koletar SL, Ellis RJ, Cohn S, Taylor M, Woods S, Heaton R, Currier J, Williams PL (2007). HIV suppression by HAART preserves cognitive function in advanced immune-reconstituted AIDS patients. AIDS 21: 1109-1117.
32. Mishra M, Vetrivel S, Sidaapa NB, Ranga U, Seth P (2008). Clade-specific differences in neurotoxicityof human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 63: 366-376.
33. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J (2008). Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 20: 25-31.
34. Parsons TD, Tucker KA, Hall CD, Robertson WT, Eron JJ, Fried MW, Robertson KR (2006). Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 20: 1591-1595.
35. Piccinini M, Rinaudo MT, Anselmino A, Buccinna B, Ramondetti C, Dematteis A, Ricotti E, Palmisano L, Mostert M, Tovo PA (2005). The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir Ther 10: 215-223.
36. Rabbitt P, Diggle P, Holland F, McInnes L (2004). Practice and drop-out effects during a 17-year longitudinal study of cognitive aging. J Gerontol B Psychol Sci Soc Sci 59: 84-97.
37. Ranga U, Shankarappa R, Siddappa NB, Ramakrishna L, Nagendran R, Mahalingam M, Mahadevan A, Jayasuryan N, Satishchandra P, Shankar SK, Prasad VR (2004). Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 78: 2586-2590.
38. Robertson K, Su Z, Krambrink A, Evans SR, Havlir DV, Margolis DM, (2007). This is your brain off drugs: neurocognitive function before and after ART discontinuation in patients with high CD4 nadir (ACTG A5170). Presented at the 14th Conference on Retro-viruses and Opportunistic Infections, Los Angeles, February 25-28.
39. Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD (2004). Highly active anti-retroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 36: 562-566.
40. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007). The prevalence and incidence of neurocogni-tive impairment in the HAART era. AIDS 21: 1915-1921.
41. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. J Neuro-Virol 8: 136-142.
42. Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, Musisi S, Ronald A, Katabira E (2006). Anti-retroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 67: 311-314.
43. Sacktor N, Nakasujja N, Skolasky R.L, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB (2009). Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 72: 165-170.
44. Sacktor N, Skolasky RL, Tarwater PM, McArthur JC, Selnes OA, Becker J, Cohen B, Visscher B, Miller EN (2003). Response to systemic HIV viral load suppression correlates with psychomotor speed performance. Neurology 61: 567-569.
45. Sacktor NC, Bacellar H, Hoover DR, Nance-Sproson TE, Selnes OA, Miller EN, Dal Pan GJ, Kleeberger C, Brown A, Saah A, McArthur JC (1996). Psychomotor slowing in HIV infection: a predictor of dementia AIDS and death. J NeuroVirol 2: 404-410.
46. Sacktor NC, Skolasky RL, Lyles RH, Esposito D, Selnes OA, McArthur JC (2000). Improvement in HIV-associated motor slowing after anti-retroviral therapy including protease inhibitors. J NeuroVirol 6: 84-88.
47. Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, Letendre S, Videen JS, McCutchan JA, Patterson TL, Grant I (2005). Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcrip-tase inhibitors. J NeuroVirol 11: 356-364.
48. Suarez S, Baril L, Stankoff B, Khellaf M, Dubois B, Lubetzki C, Bricaire F, Hauw JJ (2001). Outcome of patients with HIV-1-related cognitive impairment on highly active anti-retroviral therapy. AIDS 15: 195-200.
49. Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, De Felici FM, Benedetto A (1999). Positive and sustained effects of highly active anti-retroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 13: 1889-1897.
50. Valcour VG, Shiramizu BT, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, Ananworanich J, Siangphoe U, Kim JH, de Souza M, Degruttola V, Paul RH, Shikuma CM (2009). HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology 72: 992-998.
51. Venkataramana A, Pardo CA, McArthur JC, Kerr DA, Irani DN, Griffin JW, Burger P, Reich DS, Calabresi PA, Nath A (2006). Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 67: 383-388. (Pubitemid 44214957)
52. Verbiest W, Brown S, Cohen C, Conant M, Henry K, Hunt S, Sension M, Stein A, Stryker R, Thompson M, Schel P, Van Den Broeck R, Bloor S, Alcorn T, Van Houtte M, Larder B, Hertogs K (2001). Prevalence of HIV-1 drug resistance in anti-retroviral-naive patients: a prospective study. AIDS 15: 647-650.
53. Wojna V, Nath A (2006). Challenges to the diagnosis and management of HIV dementia. AIDS Read 16: 615-4, 626, 629.